OAS1 Antibody (E-2): sc-515518
- OAS1 Antibody (E-2) is a mouse monoclonal IgM κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 342-363 near the C-terminus of OAS1 p46 of human origin
- recommended for detection of OAS1 p46 isoform of human origin by WB, IP, IF and ELISA
- TransCruz reagent for ChIP application (sc-515518 X, 200 µg/0.1 ml)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for OAS1 Antibody (E-2). This work is in progress.
OAS1 Antibody (E-2) is a mouse monoclonal IgM antibody that detects OAS1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). OAS1 (E-2) antibody recognizes OAS1, a crucial protein that functions as a homotetramer and plays a significant role in the cellular response to viral infections. OAS1 (E-2) monoclonal antibody targets OAS1, which is primarily located in the cytoplasm, where OAS1 binds to double-stranded RNA and catalyzes the synthesis of 2′-, 5′- oligomers of adenosine, which are essential for activating the latent RNase L enzyme. The activation of RNase L leads to the degradation of single-stranded RNA, effectively inhibiting cellular protein synthesis and impairing viral replication, thereby contributing to the host′s antiviral defense mechanisms. Additionally, OAS1 is involved in the regulation of cell growth, differentiation, and apoptosis, making OAS1 a vital component in various cellular processes. With its 400 amino acid structure, OAS1 is also implicated in the interferon response and has been associated with susceptibility to diabetes mellitus, highlighting OAS1′s importance in both viral resistance and metabolic disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
OAS1 Antibody (E-2) References:
- A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. | Zhou, S., et al. 2021. Nat Med. 27: 659-667. PMID: 33633408
- OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis. | Boehmer, DFR., et al. 2021. Sci Immunol. 6: PMID: 34272227
- Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. | Huffman, JE., et al. 2022. Nat Genet. 54: 125-127. PMID: 35027740
- OAS1 rs1131454 genetic variant is associated with Alzheimer's disease: an epidemiological analysis. | Padhi, S., et al. 2022. Brain. 145: e61-e63. PMID: 35383824
- Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. | Banday, AR., et al. 2022. Nat Genet. 54: 1103-1116. PMID: 35835913
- Overexpression of OAS1 Is Correlated With Poor Prognosis in Pancreatic Cancer. | Lu, L., et al. 2022. Front Oncol. 12: 944194. PMID: 35898870
- Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types. | Jiang, S., et al. 2023. Front Oncol. 13: 1207081. PMID: 37746262
- The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma. | Luo, D., et al. 2023. Front Biosci (Landmark Ed). 28: 271. PMID: 37919050
- Resurrection of 2'-5'-oligoadenylate synthetase 1 (OAS1) from the ancestor of modern horseshoe bats blocks SARS-CoV-2 replication. | Lytras, S., et al. 2023. PLoS Biol. 21: e3002398. PMID: 38015855
- A non-canonical function of OAS1 to combat viral and bacterial infections. | Martin-Fernandez, M. and Bogunovic, D. 2024. Immunity. 57: 1721-1723. PMID: 39142270
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
OAS1 Antibody (E-2) | sc-515518 | 200 µg/ml | $322.00 | |||
OAS1 (E-2) Neutralizing Peptide | sc-515518 P | 100 µg/0.5 ml | $69.00 | |||
OAS1 Antibody (E-2) X | sc-515518 X | 200 µg/0.1 ml | $322.00 |